

# Balaxi Pharmaceuticals Limited

January 07, 2023

To,  
Listing Department,  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

**NSE Symbol: BALAXI**

**Subject: Reconciliation of Share Capital Audit Report**

Dear Sir/Madam,

Please find enclosed the Reconciliation of Share Capital Audit Report for Equity Shares of the Company for the quarter ended December 31, 2022. The report has been signed by Mr. Yogindunath S of BVR & Associates Company Secretaries LLP.

This report is submitted in compliance with Regulation 76 of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018.

This is for your information and records.

Yours Faithfully,

For **Balaxi Pharmaceuticals Limited**

**Udayan Shukla**

*(Company Secretary & Compliance Officer)*

*Membership No.: F11744*

Encl: As above

**Registered Office:**

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase III, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096

CIN: L25191TG1942PLC121598

Phone: +91 40 23555300 | Email: [info@balaxi.in](mailto:info@balaxi.in) | Website: [www.balaxipharma.in](http://www.balaxipharma.in)

To,  
**Balaxi Pharmaceuticals Limited**  
Plot No.409, H. No. 8-2-293,  
Maps Towers, 3rd Floor, Phase-III,  
Road No.81, Jubilee Hills,  
Hyderabad (T.G.) - 500096

Dear Sir/ Madam,

We have examined the relevant books, registers, forms, documents and papers produced electronically before us by **Balaxi Pharmaceuticals Limited** ('the Company') and its Registrars and Transfer Agent (RTA), Aarthi Consultants Private Limited, in respect of Reconciliation of Share Capital Audit as per Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. To the best of our knowledge and according to the information and explanations given to us, we certify the following:

**RECONCILIATION OF SHARE CAPITAL AUDIT REPORT**

1	<b>For Quarter Ended</b>	December 31, 2022
2	<b>ISIN</b>	INE618N01014
3	<b>Face Value</b>	Rs. 10/- per equity share
4	<b>Name of the Company</b>	Balaxi Pharmaceuticals Limited
5	<b>Registered Office Address</b>	Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad - 500096
6	<b>Correspondence Address</b>	Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase-III, Road No. 81, Jubilee Hills, Hyderabad - 500096
7	<b>Telephone &amp; Fax Nos.</b>	040 23555300
8	<b>Email address</b>	<u>secretarial@balaxi.in</u>
9	<b>Names of the Stock Exchanges where the company's securities are listed:</b>	National Stock Exchange of India Limited (NSE)



		Number of shares	% of Total Issued Cap.
10	<b>Issued Capital</b>	1,00,24,500	100%
11	<b>Listed Capital (Exchange wise)</b> (as per company records) National Stock Exchange of India Limited (NSE)	1,00,24,500	100%
12	<b>Held in dematerialised form in CDSL</b>	77,05,925	76.87%
13	<b>Held in dematerialised form in NSDL</b>	22,77,115	22.72%
14	<b>Physical</b>	41,460	00.41%
15	<b>Total No. of shares (12+13+14)</b>	<b>1,00,24,500</b>	<b>100.00%</b>
16	<b>Reasons for difference if any, between (10&amp;11), (10&amp;15) , (11&amp;15)</b>	NIL	NIL

**17. Certifying the details of changes in share capital during the quarter under consideration as per Table below:**

Particulars***	No. of shares	Applied / Not Applied/ for listing	Listed on Stock Exchanges	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. appr. pending for SE
Allotment of Equity Shares on Preferential Basis on October 11, 2022	24,500	Already Listed	Yes, Listed on NSE	Yes	Yes	NA

\*\*\* Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, Any other (to specify).

18	<b>Register of Members is updated (Yes/ No )</b>	Yes
19	<b>Reference of previous quarter with regards to excess dematerialized shares, if any.</b>	NIL



20	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason why?	Not Applicable
----	--	----------------

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay:

Total No. of demat requests	No. of requests	No. of shares	Reasons for delay
Confirmed after 21 Days	NIL	NIL	NA
Pending for more than 21 days	NIL	NIL	NA

22	Name, Telephone & Fax No. of the Compliance Officer of the Company.	<b>Udayan Shukla</b> Telephone No.: 040 2355 5300 Email: <a href="mailto:secretarial@balaxi.in">secretarial@balaxi.in</a>
23	Name, Address, Tel. & Fax No., Regn. no. of the Practicing Company Secretary certifying the report	<b>CS. Yogindunath S</b> BVR & Associates Company Secretaries LLP, Swastika, First Floor, Chitteth Building, P C Road, Vytilla P.O, Cochin- 682019 Tel: 0484-4046696 Membership No.: 7865 Certificate of Practice No.: 9137 Peer Review No.: P2010KE020500



24	<b>Appointment of common agency for share registry work (if yes, name and address)</b>	<b>Aarthi Consultants Private Limited</b> 1-2-285, Domalguda, Hyderabad-500029 Ph: 040-27638111, 27634445 Fax: 040-27632184
25	<b>Any other detail that the Company Secretary may like to provide. (e.g. BIFR company, delisting from SE,</b>	Mr. Udayan Shukla was appointed as the Compliance Officer of the Company with effect from October 11, 2022. Further, He was appointed and designated as the Company Secretary of the Company with effect from November 05, 2022.

YOGINDUNATH. S.  
Designated Partner  
BVR & Associates Company Secretaries LLP  
"Swastika", Chitteth Building  
PC Road, Ponnuranni (E)  
Vyttila P.O., Cochin - 682 019  
C P No: 9137, FCS 7865  
LLP IN AAE - 7079

*Yogindunath S.*

**CS Yogindunath S**  
**BVR & Associates Company Secretaries LLP,**  
**Practicing Company Secretaries**  
**M NO:7865**  
**CP:9137**  
**UDIN: F007865D002905276**

Date: 07-01-2023

Place: Cochin

